Page 43

Houston Methodist Foundation Magazine | 2014

An example of the type of promising drug repositioning opportunities available includes the discovery of a new molecule that was tested as a post- heart attack treatment. While the drug failed in its intended heart therapy purpose, preliminary findings in patient-derived animal models show that it may provide a novel approach to overcoming treatment resistant triple-negative breast cancer. Currently, no targeted treatment exists for this aggressive form of breast cancer. “Cancer care is more science than art, but you need to be able to provide the most effective treatment and encourage new findings in treatment and research while having the ability to help patients and their families through a difficult time,” Dr. Chang says. The Baucums, she says, showed amazing strength and courage throughout, and Vicki endured her rigorous treatment with great stoicism. Vicki says, “A very important ingredient in this process is having faith in God, your doctors and yourself. Triple-negative breast cancer is a disease the world doesn’t really know much about. “But, if you’re going to receive a triple- negative breast cancer diagnosis, Houston Methodist is where you need to be,” Vicki says. “Trial and discovery, plus faith- based medicine – it’s truly the Houston Methodist Cancer Center way.” Dr. Jenny Chang’s pioneering work has helped transform triple-negative breast cancer research, providing hope for those diagnosed with this aggressive disease. houstonmethodist.org/foundation 41


Houston Methodist Foundation Magazine | 2014
To see the actual publication please follow the link above